Several other research firms have also recently commented on ZYNE. Cantor Fitzgerald set a $21.00 target price on Zynerba Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, December 5th. Zacks Investment Research upgraded Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research note on Saturday, January 19th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Zynerba Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $14.00.
Shares of NASDAQ:ZYNE traded down $0.27 during trading